MassDevice Q&A: John McDonough

August 4, 2009 by Joe Nowlan

The T2 Biosystems CEO on the company's innovative, miniaturized diagnostic tool, the importance of de-risking before you hit the fundraising trail and why the U.S. intelligence community is interested in T2's technology.

John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.

Bullish on his 22-employee company's prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2's diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

The FDA is ramping up its cybersecurity labs and may start rejecting insecure technologies sooner than you think.

Transcend Medical CEO Brian Walsh tells MassDevice.com why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp